Wellesley Pharmaceuticals Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 1

Employees
  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $10M

  • Investors
  • 3

Wellesley Pharmaceuticals General Information

Description

Developer of a pharmaceutical platform intended to treat nocturia disease of patients. The company's platform assists in treating the frequent need to urinate at night and to eliminate nocturia symptoms which can be disseminated, enabling patients to sleep well at night without using the bathroom.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 3 Valley View Drive
  • Newtown, PA 18940
  • United States
+1 (215) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Wellesley Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 18-Apr-2016 $10M 000.00 0000 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 01-Apr-2015 00.00 00.000 0000 Completed Clinical Trials - Phase 2
2. Angel (individual) 01-Oct-2014 $550K $1.05M 000.00 Completed Clinical Trials - Phase 2
1. Angel (individual) 11-Jun-2014 $500K $500K 000.00 Completed Clinical Trials - Phase 2
To view Wellesley Pharmaceuticals’s complete valuation and funding history, request access »

Wellesley Pharmaceuticals Patents

Wellesley Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190374474-A1 Pharmaceutical compositions and methods for weight loss Abandoned 11-Jun-2018 0000000000 0
JP-2018538310-A Composition for reducing the frequency of urination, and methods of making and using the same Pending 18-Dec-2015 000000000
AU-2016370313-A1 Composition for reducing frequency of urination, method of making and use thereof Abandoned 18-Dec-2015 000000000
EP-3389661-A1 Composition for reducing frequency of urination, method of making and use thereof Withdrawn 18-Dec-2015 000000000
EP-3389661-A4 Composition for reducing frequency of urination, method of making and use thereof Withdrawn 18-Dec-2015 A61K9/28 0
To view Wellesley Pharmaceuticals’s complete patent history, request access »

Wellesley Pharmaceuticals Executive Team (2)

Name Title Board Seat Contact Info
David Dill Founder, Chief Executive Officer, President and Chairman
You’re viewing 1 of 2 executive team members. Get the full list »

Wellesley Pharmaceuticals Board Members (7)

Name Representing Role Since
David Dill Wellesley Pharmaceuticals Founder, Chief Executive Officer, President and Chairman 000 0000
John Balian Self Board Member 000 0000
Jukka Karjalainen MD Self Board Member 000 0000
Michael Myers Ph.D Self Board Member 000 0000
You’re viewing 4 of 7 board members. Get the full list »

Wellesley Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Wellesley Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cliff Miller Angel (individual) Minority 000 0000 000000 0
Axella Bioventures Venture Capital Minority 000 0000 000000 0
Keiretsu Forum Venture Capital Minority 000 0000 000000 0
To view Wellesley Pharmaceuticals’s complete investors history, request access »